Treatment-free remission in Chronic Myeloid Leukemia harboring atypical BCR-ABL1 transcripts.
Discontinuation of tyrosine kinase inhibitors (TKI) is the main goal today in the field of Philadelphia positive chronic myeloid leukemia (Ph + CML) and the criteria to attempt the interruption of therapy are well defined and rely on the possibility to regularly monitor the BCR-ABL1 transcript. Pati...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
PAGEPress Publications
2020-08-01
|
| Series: | Mediterranean Journal of Hematology and Infectious Diseases |
| Online Access: | https://www.mjhid.org/index.php/mjhid/article/view/4306 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Discontinuation of tyrosine kinase inhibitors (TKI) is the main goal today in the field of Philadelphia positive chronic myeloid leukemia (Ph + CML) and the criteria to attempt the interruption of therapy are well defined and rely on the possibility to regularly monitor the BCR-ABL1 transcript. Patients harboring atypical transcripts are automatically excluded from protocols due to the absence of a standardized method of quantification of their minimal residual disease (MRD). We report here the outcome of 6 patients with atypical transcripts with a long follow up whose MRD was followed in three cases with digital PCR during their treatment free remission (TFR). |
|---|---|
| ISSN: | 2035-3006 |